A 38-year-old woman from Delhi presents with vaginal bleeding and pelvic pain for 4 months. Cervical biopsy confirms squamous cell carcinoma. MRI pelvis shows a 4.5 cm cervical lesion with bilateral parametrial involvement and left pelvic sidewall extension. There is no hydronephrosis. Pelvic lymph nodes are enlarged (>1 cm short axis). PET-CT shows no distant metastases. What is the most appropriate primary treatment modality for this patient?

Explanation

## Cervical Cancer Treatment Selection by Stage ### Stage Assessment This patient has: - Tumor size: 4.5 cm (>4 cm) - **Parametrial involvement** (bilateral) - **Pelvic sidewall extension** (left) - Enlarged pelvic lymph nodes - No hydronephrosis **Key Point:** This constellation of findings indicates **Stage IIIB** (pelvic sidewall involvement ± parametrial extension). Pelvic sidewall extension is defined as tumor reaching the pelvic muscles/fascia or causing ureteral obstruction (hydronephrosis). ### Treatment Algorithm by Stage ```mermaid flowchart TD A[Cervical Cancer Diagnosed]:::outcome --> B{Stage?}:::decision B -->|IA-IB1| C[Radical hysterectomy + pelvic lymphadenectomy]:::action B -->|IB2-IIA| D{Patient factors?}:::decision D -->|Good surgical candidate| E[Radical hysterectomy + lymphadenectomy]:::action D -->|Poor surgical candidate| F[Concurrent chemoradiation + brachytherapy]:::action B -->|IIB-IVA| G[Concurrent chemoradiation + brachytherapy]:::action B -->|IVB| H[Palliative chemotherapy/radiation]:::urgent C --> I[Adjuvant RT/CRT if high-risk features]:::action E --> I F --> J[Brachytherapy boost]:::action G --> J ``` ### Why Concurrent Chemoradiation for Stage IIIB? | Feature | Rationale | |---------|----------| | **Pelvic sidewall involvement** | Surgical resection not feasible; requires radiation to encompass entire pelvis | | **Parametrial extension** | Extends beyond the scope of hysterectomy margins | | **Enlarged pelvic lymph nodes** | Concurrent chemotherapy (cisplatin) radiosensitizes tumor and treats nodal disease | | **No distant metastases** | Curative intent treatment appropriate | **High-Yield:** **Concurrent chemoradiation (CCRT) + brachytherapy** is the gold standard for **Stage IIB–IVA** cervical cancer. The **Cisplatin-based chemotherapy** (40 mg/m² weekly × 5–6 weeks) acts as a radiosensitizer and treats micrometastatic disease. **Clinical Pearl:** - **Stages IA–IB1:** Radical hysterectomy (Wertheim's procedure) is preferred in young, fit patients (preserves ovarian function in premenopausal women). - **Stages IB2–IVA:** CCRT + brachytherapy is standard (equivalent or superior survival to surgery with lower morbidity). - **Brachytherapy:** Delivered after EBRT (external beam radiation therapy) to deliver high-dose radiation to residual disease while sparing surrounding tissues. **Mnemonic:** **CCRT for Locally Advanced** — Concurrent Chemoradiation for stages IIB and beyond. ### Why Not Radical Hysterectomy? Surgical resection is contraindicated because: 1. **Pelvic sidewall involvement** makes complete resection impossible. 2. **Parametrial extension** beyond hysterectomy margins. 3. Risk of positive surgical margins and inadequate treatment.